Istanbul Chamber of Industry announced the results of the 'Turkey's Second 500 Largest Industrial Enterprises-2021' research, which it carried out based on net sales from production. Contributing to public health and the health sector in Turkey for 36 years, with 100 percent domestic capital, Polifarma succeeded in entering the list from the 92nd place. Polifarma's net sales from production, which is the main size criterion of the ISO Second 500 companies, amounted to 848.9 million TL.
Polifarma İlaç, which works to reduce Turkey's dependence on foreign sources and to provide easy access to drugs, and exports to more than 70 countries, is Turkey's most preferred brand in the field of serum and hospital products. Polifarma İlaç, which produces drugs and critically important serum for many therapeutic areas such as intensive care, infection, oncology, radiology, dialysis and cardiology, especially anesthesia, has production in ampoules, vials, PFS forms and approximately 600 licensed products in all forms. While rapidly developing its IV (intravenous) drug portfolio in addition to serum production, where it is the market leader, it continues to grow in the field of prescription markets.
Be the first to comment